![Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b01290/asset/images/large/jm-2017-01290b_0001.jpeg)
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry
![Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b01290/asset/images/large/jm-2017-01290b_0013.jpeg)
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry
![Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b01290/asset/images/large/jm-2017-01290b_0018.jpeg)
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma | Journal of Medicinal Chemistry
![Sustainability | Free Full-Text | Electric Vehicle-to-Grid (V2G) Technologies: Impact on the Power Grid and Battery Sustainability | Free Full-Text | Electric Vehicle-to-Grid (V2G) Technologies: Impact on the Power Grid and Battery](https://www.mdpi.com/sustainability/sustainability-14-13856/article_deploy/html/images/sustainability-14-13856-g002-550.jpg)